Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Frequently asked questions
What sector does Invion Limited (IVIXF) operate in?
Invion Limited belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Invion Limited (IVIXF) current stock price?
As of the latest data, Invion Limited stock price is $0.04, with a previous close of $0.04.
What is Invion Limited (IVIXF) current market capitalization?
Invion Limited market cap is approximately 4.08 million.
What is Invion Limited (IVIXF) Earnings Per Share (EPS)?
The trailing EPS is -$0.07.
What is Invion Limited (IVIXF) EBITDA?
Invion Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -912.38 thousand.
Does Invion Limited (IVIXF) pay dividends?
No. Invion Limited does not pay a dividend.
What is Invion Limited (IVIXF) beta (volatility) score?
Invion Limited has a beta of 0.446, indicating lower volatility than the overall market.